
The drugmaker raised its revenue and earnings forecasts as Dupixent sales and new medicines offset weakness in vaccines.
Sanofi raised its 2026 outlook after third-quarter revenue and adjusted earnings beat analysts’ expectations. The company now expects currency-adjusted revenue to grow in the low teens from 2025, while adjusted earnings per share are forecast to rise in the mid-teens.
Revenue for the quarter increased 14.3% on a currency-adjusted basis to €14.4 billion. Adjusted profit grew nearly 18% on the same basis to almost €4.3 billion, with the company citing cost discipline and lower spending on sales and advertising.
Dupixent revenue rose by more than a third. Sales of the drug totaled more than €15 billion over the first nine months of the year, while growth in new medicines helped offset a decline in vaccines.
The results also highlight Sanofi’s reliance on Dupixent before its patent protection ends. The company and Regeneron have agreed to develop four antibodies targeting type 2 inflammation, with Regeneron leading research and Sanofi handling global commercialization; they would share potential future proceeds equally.
Sanofi shares traded at €80.17, up 5.28% since the previous close, as of 13:18 UTC Friday.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.